NCT06301399

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

A Study on the Efficacy and Safety of Rituximab When Combined With Prior Targeted Therapy and Checkpoint Immunotherapy as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 17 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma

Detailed description

Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma

Conditions

• Advanced Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy	Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.

Timeline

• Start date: 2024-03-20
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2024-03-08
• Last updated: 2024-11-20

Locations

1 site across 1 country: China